GlassScriptPhysician profile
Daniel K Lee
NPI 1811193865
$1,484.34
in general payments reported to CMS, 2019-2025
27 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $175 · 2022: $33.77 · 2023: $245 · 2024: $97.51 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $186.86 | 2019 | |
| Boston Scientific Corporation | $162.02 | 2023 | |
| Merck Sharp & Dohme LLC | $144.20 | 2019-2025 | Lagevrio, Verquvo |
| Novo Nordisk INC | $111.33 | 2023-2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $109.62 | 2019-2020 | |
| Exact Sciences Corporation | $96.45 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $81.79 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $60.81 | 2024-2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $57.62 | 2019-2025 | Breztri |
| Abbvie INC. | $46.96 | 2024-2025 | |
| Amgen INC. | $42.54 | 2019-2023 | Repatha |
| Dexcom, INC. | $41.08 | 2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $33.77 | 2022 | |
| Sun Pharmaceutical Industries INC. | $33.44 | 2023 | Cequa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.96 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $29.91 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.85 | 2019-2020 | |
| Ucb, INC. | $27.14 | 2019 | |
| Sanofi Pasteur INC. | $25.80 | 2019-2020 | |
| Astellas Pharma US INC | $23.34 | 2019-2020 | |
| Braintree Laboratories, INC. | $19.48 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.40 | 2025 | |
| Azurity Pharmaceuticals, INC. | $17.79 | 2025 | Edarbi |
| Biotronik Nro, INC. | $14.74 | 2025 | Prospera |
| Glaxosmithkline, LLC. | $13.56 | 2020 | |
| Amarin Pharma, INC. | $12.95 | 2020 | |
| Advanced Respiratory, INC | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.